It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Alzheimer’s disease (AD) is the most common form of dementia, characterized by accumulation of amyloid β (Aβ) and neurofibrillary tangles. Oxidative stress and inflammation are considered to play an important role in the development and progression of AD. However, the extent to which these events contribute to the Aβ pathologies remains unclear. We performed inter-species comparative gene expression profiling between AD patient brains and the AppNL-G-F/NL-G-F and 3xTg-AD-H mouse models. Genes commonly altered in AppNL-G-F/NL-G-F and human AD cortices correlated with the inflammatory response or immunological disease. Among them, expression of AD-related genes (C4a/C4b, Cd74, Ctss, Gfap, Nfe2l2, Phyhd1, S100b, Tf, Tgfbr2, and Vim) was increased in the AppNL-G-F/NL-G-F cortex as Aβ amyloidosis progressed with exacerbated gliosis, while genes commonly altered in the 3xTg-AD-H and human AD cortices correlated with neurological disease. The AppNL-G-F/NL-G-F cortex also had altered expression of genes (Abi3, Apoe, Bin2, Cd33, Ctsc, Dock2, Fcer1g, Frmd6, Hck, Inpp5D, Ly86, Plcg2, Trem2, Tyrobp) defined as risk factors for AD by genome-wide association study or identified as genetic nodes in late-onset AD. These results suggest a strong correlation between cortical Aβ amyloidosis and the neuroinflammatory response and provide a better understanding of the involvement of gender effects in the development of AD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Medical Institute of Bioregulation, Kyushu University, Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Fukuoka, Japan (GRID:grid.177174.3) (ISNI:0000 0001 2242 4849)
2 Medical Institute of Bioregulation, Kyushu University, Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Fukuoka, Japan (GRID:grid.177174.3) (ISNI:0000 0001 2242 4849); University of California, San Francisco, Department of Neurology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
3 RIKEN Brain Science Institute, Laboratory for Proteolytic Neuroscience, Saitama, Japan (GRID:grid.474690.8)
4 Medical Institute of Bioregulation, Kyushu University, Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Fukuoka, Japan (GRID:grid.177174.3) (ISNI:0000 0001 2242 4849); Japan Community Health Care Organization Kyushu Hospital, Department of Neurosurgery, Kitakyushu, Japan (GRID:grid.460253.6)
5 Graduate School of Medical Sciences, Kyushu University, Department of Neuropathology, Neurological Institute, Fukuoka, Japan (GRID:grid.177174.3) (ISNI:0000 0001 2242 4849)
6 Graduate School of Medical Sciences, Kyushu University, Department of Neuropsychiatry, Fukuoka, Japan (GRID:grid.177174.3) (ISNI:0000 0001 2242 4849)
7 Graduate School of Medical Sciences, Kyushu University, Department of Epidemiology and Public Health, Fukuoka, Japan (GRID:grid.177174.3) (ISNI:0000 0001 2242 4849)
8 Hisayama Research Institute for Lifestyle Diseases, Hisayama, Fukuoka, Japan (GRID:grid.482571.d)
9 University of California, Department of Neurobiology and Behavior, Irvine, USA (GRID:grid.266093.8) (ISNI:0000 0001 0668 7243)